Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2001-02-23
2010-02-09
Helms, Larry R. (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C530S300000, C530S350000
Reexamination Certificate
active
07659073
ABSTRACT:
Inactive precursor forms of PSA (pPSA) have been identified to exist in serum and tissues of patients with prostate cancer. Antibodies specific for pPSA are provided. Methods for detecting inactive precursors of PSA in human physiological fluid and tissues are also provided, as well as diagnostic kits and methods useful in the diagnosis and management of prostate cancer.
REFERENCES:
patent: 7288636 (2007-10-01), Mikolajczyk et al.
patent: 0 725 139 (1996-08-01), None
patent: 0 843 006 (1998-05-01), None
patent: WO 94/10343 (1994-05-01), None
patent: WO 96/34964 (1996-11-01), None
patent: WO 98/49323 (1998-11-01), None
Lin et al, 1998, Urology, 52: 366-371.
Kibel, AS et al, 2000, J urol, 164(1): 192-6.
Dong et al, 2000, Cancer Research, 60: 3880-3883.
Zhau, HE, 1994, J Cell Biochem, Suppl 19: 208-216.
W.J. Catalona, M.D., et al. Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer. N. Engl J Med, 324: 1156-1161, 1991.
J.E. Oesterling, Prostate Specific Antigen: A Critical Assessment of the Most Useful Tumor Marker for Adenocarcinoma of the Prostate. J Urol, 145: 907-923, 1991.
F. Labrie, et al., Serum Prostate Specific Antigen as Pre-screening Test for Prostate Cancer. J Urol, 147: 846-851, 1992.
H. Lilja, et al. Prostate-Specific Antigen in Serum Occurs Predominantly in Complex with α1-Antichymotrypsin. Clin Chem, 37: 1618-1625, 1991.
U.H. Stenman, et al. A Complex Between Prostate-specific Antigen and α1-Antichymotrypsin Is the Major Form of Prostate-specific Antigen in Serum of Patients with Prostatic Cancer: Assay of the Complex Improves Clinical Sensitivity for Cancer. Cancer Res., 51: 222-226, 1991.
W.J. Catalona, M.D., et al. Use of the Percentage of Free Prostate-specific Antigen to Enhance Differentiation of Prostate Cancer from Benign Prostatic Diease: A Prospective Multicenter Clinical Trial. Jama, 279: 1542-1547, 1998.
D. L. Woodrum, et al. Interpretation of Free Prostate Specific Antigen Clinical Research Studies for the Detection of Prostate Cancer. J Urol, 159: 5-12, 1998.
J. Peter, et al. Analysis of Free Prostate-specific Antigen (PSA) after Chemical Release from the Complex with α1-Antichymotrypsin (PSA-ACT). Clin. Chem 46: 474-482, 2000.
J. Noldus, et al. Isolation and Characterization of Free Form Prostate Specific Antigen (f-PSA) in Sera of Men With Prostate Cancer. J Urol., 158: 1606-1609, 1997.
H. Hilz, et al. Molecular Heterogeneity of Free PSA in Sera of Patients with Benign and Malignant Prostate Tumors [In Process Citation]. Eur Urol, 36: 286-292, 1999.
E. Paus, et al. Epitope Mapping and Affinity Estimation of 83 Antibodies against Prostate-Specific Antigen. Tumor. Biol., 20: 52-69, (Suppl 1)1999.
P. Nurmikko, et al. Production and Characterization of Novel Anti-Prostate-specific Antigen (PSA) Monoclonal Atibodies That Do Not Detect Internally Cleaved Lysl45-Lysl46 Inactive PSA [In Process Citation]. Clin.Chem., 46: 1610-1618, 2000.
T.J. Wang, et al. Western Blotting Analysis of Antibodies to Prostate-Specific antigen: Cross-Reactivity with Human Kallikrein-2. Tumor Biol, 20: 75-78 (Suppl. 1), 1997.
T.J. Wang, et al. Western Blotting Analysis of Antibodies to Prostate-Specific Antigen: Specificities for Prostate-Specific Antigen and Prostate-Specific Antigen Fragments. Tumor Biol., 20: 79-85 (suppl 1) 1999.
J. A. Finlay, et al. Polyclonal and Monoclonal Antibodies to Prostate-Specific Antigen Can Cross-React with Human Kallkrein 2 and Human Kallikrein 1. Urology, 53: 746-751, 1999.
A. Kumar, et al. Expression of Pro Form of Prostate-specific Antigen by Mammalian Cells and Its Conversion to Mature, Active Form by Human Kallikrein 2. Cancer Res, 57: 3111-3114, 1997.
A. Christensson, et al. Enzymatic Activity of Prostate-specific Antigen and Its Reactions with Extracellular Serine Proteinase Inhibitors. Eur J Biochem, 194: 755-763, 1990.
A. Kumar, et al. Expression of Human Glandular Kallikrein, hK2, in Mammalian Cells. Cancer Res., 56: 5397-5402, 1996.
S. D. Mikolajczyk, et al., “BPSA,” A Specific Molecular Form of Free Prostate-Specific Antigen, Is Found Predominantly in the Transition Zone of Patients with Nodular Benign Prostatic Hyperplasia. Urology, 55: 41-45, 2000.
T. J. Wang, et al., Benign Prostatic Hyperplasia-Associated Prostate-Specific Antigen (BPSA) Shows Unique Immunoreactivity with Anti-PSA Monoclonal Antibodies. Eur.J.Biochem., 267: 4040-4045, 2000.
C. K. Naughton, et al., Clinical and Pathologic Tumor Characteristics of Prostate Cancer As A Function of the Number of Biopsy Cores: A Retrospecitve Study. Urology, 52: 808-813, 1998.
J. Lövgren, et al., Activation of the Zymogen Form of Prostate-Specific Antigen by Human Glandular Kallikrein 2. JBiol.Biophys.Res. Comm., 238: 549-555, 1997.
T. K. Takayama, et al., Characterization of the Precursor of Prostate-specific Antigen [Activation by Trypsin And by Human Glandular Kallikerin]. J.Biol.Chem., 272: 21582-21588, 1997.
M. F. Darson, et al., Human Glandular Kallikrein 2 (hK2) Expression in Prostatic Intraepithelial Neoplasia and Adenocarcinoma: A Novel Prostate Cancer Marker. Urology, 49(6): 857-862, 1997.
S. D. Mikolajczyk, et al., A Precursor Form of Prostate-specific Antigen Is More Highly Elevated in Prostate Cancer Compared with Benign Transition Zone Prostate Tissue. Cancer Res., 60: 756-759, 2000.
W. J. Catalona, Clinical Utility of Measurements of Free and Total Prostate-Specific Antigen (PSA): A Review. Prostate,Supplement 7: 64-69, 1996.
Mikolajczyk, S.D., et al., “A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer,”Cancer Researchvol. 61, 18:6958-6963 (Sep. 15, 2001).
Peter, J., et al., “Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry,”Cancer Researchvol. 61, 3:957-962 (Feb. 1, 2001).
Hill, T., et al., “Development of PROhK2 Specific Assay,”Tumor Biol. 18:7, Karger (1997).
Karr, J.F., et al., “The Presence of Prostate-specific Antigen-related Genes in Primates and the Expression of Recombinant Human Prostate-specific Antigen in a Transfected Murine Cell Line,”Cancer Res. 55:2455-2462, American Association for Cancer Research, Inc. (1995).
Kurkela, R., et al., “Expression of Active, Secreted Human Prostate-specific Antigen by Recombinant Baculovirus-infected Insect Cells on a Pilot-scale,”Biotechnology 13:1230-1234, Nature Publishing Co. (1995).
Lövgren, J., et al., “Production of Recombinant PSA and hK2 and Analysis of Their Immunologic Cross-Reactivity,”Biochem. Biophys. Res. Comm. 213:888-895, Academic Press, Inc. (1995).
Pettersson, K., et al., “Free and Complexed Prostate-Specific Antigen (PSA): In Vitro Stability, Epitope Map, and Development of Immunofluorometric Assays for Specific and Sensitive Detection of Free PSA and PSA-α1-Antichymotrypsin Complex,”Clin. Chem. 41:1480-1488, American Association for Clinical Chemistry, Inc. (1995).
Charlesworth, M.C., et al., “Detection of a Prostate-Specific Protein, Human Glandular Kallikrein (hK2), in Sera of Patients with Elevated Prostate-Specific Antigen Levels,”Urology 49:487-493, Elsevier Science Inc. (1997).
Kumar, A., et al., “Expression of Human Glandular Kallikrein, hK2, in Mammalian Cells,”Cancer Res. 56:5397-5402, American Association for Cancer Research (1996).
McCormack, R.T., et al., “Molecular Forms of Prostate-Specific Antigen and the Human Kallikrein Gene Family: A New Era,”Urology 45:729-744, Elsevier Science (1995).
Japanese Office Action, Patent Application No. 10-547269, mailed on Oct. 14, 2008, 6 pages.
English language translation of Japanese Office Action, Patent Application No. 10-547269, mailed on Oct. 14, 2008, 5 pages (listed on accompanying PTO/SB/08B as NPL11).
Dialog File 351, Accession No. 7344186, English language abstract for JP 6343476 A (listed on accompanying PTO/SB/08A as FP6).
Dialog File 351, Accession No. 6192703, Engli
Mikolajczyk Stephen D.
Rittenhouse Harry G.
Wang Tang Jang
Wolfert Robert L.
Davis Minh-Tam
Helms Larry R.
Hybritech Incorporated
Murphy Anna M.
Sterne Kessler Goldstein & Fox PLLC
LandOfFree
Forms of prostate specific antigens and methods for their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Forms of prostate specific antigens and methods for their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Forms of prostate specific antigens and methods for their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4165461